Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study
Authors:
- Shahab AbtahiSAShahab Abtahi
- René CordtzRCRené Cordtz
- Lene DreyerLDLene Dreyer
- Johanna H M DriessenJDJohanna H M Driessen
- Annelies BoonenABAnnelies Boonen
- Andrea M BurdenABAndrea M Burden
- 5 February 2022
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (7) , 879-888.e3
Abstract
No abstract availableKeywords
Funding Information
- UCB
- Eli Lilly and Company
- Galápagos
- AbbVie
- Boehringer Ingelheim
This publication has 36 references indexed in Scilit:
- Metformin and the Risk of CancerDiabetes Care, 2012
- Circulating Dickkopf-1 Is Correlated with Bone Erosion and Inflammation in Rheumatoid ArthritisThe Journal of Rheumatology, 2011
- Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritisArthritis Research & Therapy, 2010
- Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER studyAnnals of the Rheumatic Diseases, 2009
- Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone lossAnnals of the Rheumatic Diseases, 2009
- Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritisAnnals of the Rheumatic Diseases, 2009
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximabArthritis Research & Therapy, 2007
- Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006